Nemocnice Nymburk, s.r.o.
- Address
- lock Available on a paid plan
Nemocnice Nymburk, s.r.o. - Hematology and Coagulation Disorders Research
Nemocnice Nymburk, s.r.o. is a clinical research facility with specialized expertise in rare hematological conditions and coagulation disorders. The center demonstrates particular proficiency in evaluating therapeutic interventions for patients with inherited blood clotting abnormalities, focusing on perioperative and obstetric care scenarios where thrombotic risk is significantly elevated.
- Congenital antithrombin deficiency and thrombophilia management
- Perioperative hemostasis and anticoagulation therapy
- Prevention of thromboembolic complications during surgery and delivery
The center's research portfolio emphasizes the critical assessment of antithrombin replacement therapy in high-risk clinical situations, including surgical procedures and parturition. Through rigorous evaluation of thrombotic and thromboembolic events, Nemocnice Nymburk contributes valuable evidence for managing patients with rare coagulation factor deficiencies, helping to optimize safety outcomes during vulnerable perioperative and obstetric periods.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Octapharma AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nemocnice Nymburk, s.r.o.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Efficacy and Safety of Antithrombin III Human in Patients with Congenital Antithrombin Deficiency Undergoing Surgical Procedures or Parturition | Octapharma AG | Phase III | Recruiting | Feb 2023 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Antithrombin Iii Human | 1 | Unknown | 2023-02-14 | 2023-02-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.